Cancer Clinical Trial -Istari Oncology-LUMINOS-102

LUMINOS-102: Lerapolturev With or Without Immune Checkpoint Blockade in Advanced PD-1 Refractory Melanoma

Drug

Lerapolturev, Anti-PD-1 Checkpoint Inhibitor

Phase

Phase II

Condition

Melanoma

Keywords

PRL3+